A novel diagnostic test to identify Covid variations has been introduced by South Korean biotechnology company Seegene.

A novel diagnostic test to identify Covid variations has been introduced by South Korean biotechnology company Seegene.

The well-known South Korean biotechnology firm Seegene recently declared that it had successfully finished the first variant diagnostics test for Covid 19. With only one multiplex real-time PCR test, the new test can now identify several Covid strain types. The test is called the “AllplexTM SARS-CoV-2 Master Assay,” and it can identify Covid19 as well as other Covid variations in the initial testing. This approach is highly useful because the pandemic has recently changed into more contagious versions and has spread to more than 70 nations.

With the addition of the newly defined viral variants B.1.351 from South Africa, B.1.1.7 from the UK, P.1 from Brazil, and B.1.1.207 from the US, the new testing method will now be able to detect a total of 10 targets, including 4 Covid genes. Only Seegene’s testing process makes it feasible to identify four different strain types in a single test, and it is crucial to do the same since it is simpler to distinguish between the strains as the virus keeps changing quickly. Dr. Jong-Yoon Chun, the CEO of Seegene, has said that the testing burden can be significantly lessened with this new approach, and his business would continue to monitor the virus for new varieties.